Diabetes research

Have you considered participating in a clinical study which might improve future treatment options? Research has shown that treatment with injectable semaglutide can reduce the risk of stroke and heart attack in people with Type 2 diabetes. The SOUL study has been designed to confirm and better understand these findings by comparing semaglutide tablets against placebo (“dummy” medication) for a period of 3–5 years.

You may qualify to participate in the study if:

• You have type 2 diabetes
• You are 50 years of age or older
• Have heart disease or kidney disease
• You are able and willing to adhere to study procedures

Principal Investigator – Dr Hammond

We are recruiting children (over 5 years) and adults diagnosed with Type 1 Diabetes in the last 6 months to the ADDRESS 2 study. The After Diagnosis Diabetes REsearch Support System aims to provide researchers with a resource of people that can be approached for cutting edge research. There are new studies that require early recruitment / treatment so to make this possible the people that have joined ADDRESS 2 would be approached directly. If you are interested please contact one of the Research team for further information.

Principal Investigators – Dr Hammond (Adults) and Dr Rahman (Children)

TrialNet is an international network of sites across the world, based out of the University of Florida.  This network is dedicated to the study, prevention, and early treatment of Type 1 diabetes.

Pathway To Prevention Trial:
We are recruiting close family members of people who have Type 1 Diabetes because they are likely to be at higher risk of developing it themselves.  The aim of the study is to learn more about how diabetes occurs by looking at early markers of diabetes in the blood.

We offer screening for relatives of people who have Type 1 Diabetes, and monitoring for those found to be at high risk of developing Type 1 Diabetes.

If found to be eligible, there is also the opportunity to take part in trials here at Harrogate that may also prevent or delay the onset of Type 1 Diabetes.

Click here to visit the Pathway to Prevention Study website. 

Abatacept Trial:
This trial is for people who are found to be high risk of developing Type 1 Diabetes.

The purpose of the study is to see if giving a medication called abatacept can help delay or prevent the development of abnormal glucose levels and diabetes in people who have markers associated with risk of type 1 diabetes (autoantibodies).

Click here to visit the Abatacept study website.

LIFT Trial:

This trial is for patients who develop Type 1 Diabetes while in one of our TrialNet studies. The LIFT Study (Long-Term Investigative Follow-Up in TrialNet) gives participants personal ongoing monitoring by experts at the forefront of T1D research.

This is the only clinical study in the world that is following people with Type 1 Diabetes before, during and after diagnosis.

Long-term follow up will help us answer questions about what happens in the stages of T1D.

Click here to visit the LIFT study website.

www.trialnet.org

Twitter: @T1D_TrialNet

Facebook: DiabetesTrialNet

Principal Investigator – Laura Dinning

This trial recruited patients from GP practices with known pre-diabetes (impaired glucose tolerance based on blood tests screening for diabetes called an HbA1c).

Patients are followed up for two years following initial education on diet and lifestyle advice then randomised to receive three times weekly text messages providing lifestyle advice, or not.

This trial was sponsored by Imperial College, London

Principal Investigator – Dr Hammond

This was an observational trial for patients with Type 1 and Type 2 Diabetes who were identified as clinically appropriate to commence Insulin Degludec (Tresiba).  It is investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus.

It followed patients before and after treatment commenced. Follow up was for 12 months.

This trial was sponsored by Novo Nordisk.

Principal Investigator – Dr Ray

This trial recruited patients with Type 1 Diabetes on insulin pump therapy, to use a new insulin. Follow up was for six months.

This was sponsored by Novo Nordisk®.

Principal Investigator – Dr Maguire

This trial set out to demonstrate whether the application of LeucoPatch® (a novel wound care product produced from the patient’s own venous blood, the final product comprising of a thin circular plug) used in conjunction with usual care is superior to usual care alone. Follow up was for six months.

This was sponsored by Nottingham Clinical Trials Unit.

Principal Investigator – Dr Hammond

This pilot trial involved delivery of the ‘WICKED’ course to people aged 16-25 transitioning from paediatric to adult diabetes services.

Working with insulin, carbohydrates, ketones and exercise to manage diabetes: exploration of potential for implementation into clinical practice. Follow up after course attendance was for 12 months.

Click this link to find out about the WICKED course.

This was sponsored by the Sheffield Clinical Trials Unit.

Principal Investigator – Dr Hammond

This trial recruited patients with Type 2 Diabetes who required optimisation of their long acting insulin regimen.  This was a ‘real world’ observational trial comparing lixisenatide to other injectable intensification therapy.

This trial was sponsored by Sanofi Aventis.